Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Trial Pipeline
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT06974981
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
NCT03184038
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02757859
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
NCT03796884
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
NCT03251027
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
NCT02068586
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
NCT01655836
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT03472573
Decision Counseling Program in Increasing Shared Decision Making and Clinical Trial Participation in Patients With Stage 0-IV Lung Cancer (Free to Breathe)
NCT03820557
Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery
NCT03297112
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
NCT03039413
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
NCT02583893
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
NCT02186509
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT01818063
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
NCT01878695
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
NCT01356628
Digoxin for Recurrent Prostate Cancer
NCT01162135
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
NCT01184885
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
NCT00838929
Fatigue and Pancreas and Bile Duct Cancer Study
NCT00902759
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
NCT00806611
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
NCT00437372
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
NCT00429143
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
NCT00328783
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00003268
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 7 |
| Phase 3 | 1 |
What the Pipeline for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Shows
According to the ClinicalTrials.gov registry, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University is linked to 26 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 12% of the sponsor's indexed portfolio — and 18 are already marked complete, representing roughly 69% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 19 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University is Pancreatic Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.